Febuxostat, a novel, orally administered, potent, non–purine analogue, xanthine oxidase inhibitor in the management of hyperuricemia in patients with gout & chronic tophaceous gout. It has minimal effects on other enzymes involved in purine and pyrimidine metabolism, and is metabolized mainly by glucuronide formation and oxidation in the liver. In a study of subjects with renal impairment, the serum urate–lowering effect of febuxostat was unaltered. Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.
Key words: Febuxostat, xanthine oxidase inhibitor, chronic tophaceous gout, renal impairment
|